BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21964531)

  • 1. Prolonged survival in patients with lung cancer with diabetes mellitus.
    Hatlen P; Grønberg BH; Langhammer A; Carlsen SM; Amundsen T
    J Thorac Oncol; 2011 Nov; 6(11):1810-7. PubMed ID: 21964531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002.
    Sawabata N; Asamura H; Goya T; Mori M; Nakanishi Y; Eguchi K; Koshiishi Y; Okumura M; Miyaoka E; Fujii Y;
    J Thorac Oncol; 2010 Sep; 5(9):1369-75. PubMed ID: 20683209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged survival in lung cancer patients with diabetes mellitus.
    Kurishima K; Satoh H
    J Thorac Oncol; 2012 Sep; 7(9):e17-8; author reply e17. PubMed ID: 22895151
    [No Abstract]   [Full Text] [Related]  

  • 4. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
    Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
    J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year survival does not equal cure in non-small cell lung cancer: a Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival.
    Hubbard MO; Fu P; Margevicius S; Dowlati A; Linden PA
    J Thorac Cardiovasc Surg; 2012 Jun; 143(6):1307-13. PubMed ID: 22361247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).
    Decroisette C; Monnet I; Berard H; Quere G; Le Caer H; Bota S; Audigier-Valette C; Geriniere L; Vernejoux JM; Chouaid C;
    J Thorac Oncol; 2011 Mar; 6(3):576-82. PubMed ID: 21270669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.
    Aarts MJ; van den Borne BE; Biesma B; Kloover JS; Aerts JG; Lemmens VE
    Int J Cancer; 2015 Mar; 136(5):E387-95. PubMed ID: 25219898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
    Zinner RG; Novello S; Peng G; Herbst R; Obasaju C; Scagliotti G
    Clin Lung Cancer; 2010 Mar; 11(2):126-31. PubMed ID: 20199979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience of cancer care for metastasis-induced acute pancreatitis patients with lung cancer.
    Liu SF; Zhang S; Chen YC; Fang WF; Lin MC; Su MC; Wang CC
    J Thorac Oncol; 2009 Oct; 4(10):1231-5. PubMed ID: 19692933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
    Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
    J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of the simplified comorbidity score in the treatment of small cell lung carcinoma.
    Kuo YW; Jerng JS; Shih JY; Chen KY; Yu CJ; Yang PC
    J Thorac Oncol; 2011 Feb; 6(2):378-83. PubMed ID: 21173715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
    Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M
    J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A national study of nodal upstaging after thoracoscopic versus open lobectomy for clinical stage I lung cancer.
    Licht PB; Jørgensen OD; Ladegaard L; Jakobsen E
    Ann Thorac Surg; 2013 Sep; 96(3):943-9; discussion 949-50. PubMed ID: 23684159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A retrospective study of the impact of diabetes mellitus on survival in patients with lung cancer].
    Han R; Yang G; Lyu Z; Gu W; Du J; Jin N; Zang L; Yang L; Guo Q; Ba J; Dou J; Mu Y
    Zhonghua Nei Ke Za Zhi; 2015 Dec; 54(12):1028-31. PubMed ID: 26887369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of vascular and lymphovascular invasion in early lung cancer.
    Al-Alao BS; Gately K; Nicholson S; McGovern E; Young VK; O'Byrne KJ
    Asian Cardiovasc Thorac Ann; 2014 Jan; 22(1):55-64. PubMed ID: 24585645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.
    Kosmidis PA; Syrigos K; Kalofonos HP; Dimopoulos MA; Skarlos D; Pavlidis N; Boukovinas I; Bafaloukos D; Pectasides D; Bacoyiannis C; Fountzilas G
    Anticancer Res; 2012 Jan; 32(1):175-81. PubMed ID: 22213304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of Stage II non-small cell lung cancer according to tumor and nodal status at diagnosis.
    Wisnivesky JP; Henschke C; McGinn T; Iannuzzi MC
    Lung Cancer; 2005 Aug; 49(2):181-6. PubMed ID: 16022911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
    Kubota K; Niho S; Enatsu S; Nambu Y; Nishiwaki Y; Saijo N; Fukuoka M
    J Thorac Oncol; 2009 Dec; 4(12):1530-6. PubMed ID: 19755925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry.
    Ou SH; Zell JA
    J Thorac Oncol; 2008 Mar; 3(3):216-27. PubMed ID: 18317063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.